Fifteen-Year Outcomes of the ProtecT Trial for Localized Prostate Cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Utilization and Cancer Control Outcomes of Active Surveillance Amongst Black and White Men with Intermediate Risk Prostate Cancer in a Population-Based Analysis.Journal of racial and ethnic health disparities · 2026
   Article
2. Initial non-curative treatment for favorable intermediate-risk prostate cancer.International urology and nephrology · 2026
   Article
3. Early outcomes after focal high-dose-rate brachytherapy in low- and favorable intermediate-risk prostate cancer: promising early results from a prospective randomized trial.Open medicine (Warsaw, Poland) · 2026
   Article
4. Upstaging of Patients Diagnosed with Favorable Intermediate-Risk Prostate Cancer-Is Active Surveillance Really a Suitable Approach for All These Patients?Cancers · 2025
   Article

Corrections and comments

• Comment on
  Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.2023

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as